Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Recurrent High-grade Glioma Clinical Trial

Official title: Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Status Not yet recruiting

Clinical Trial Summary

This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.

Clinical Trial Description

This trial is aimed at evaluating the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas. And, this trial is approved by medical ethics committee of Hebei Yanda Hospital.Researchers will conduct thsi trial from 2015/05 to 2018/05, and 30 recurrent high-grade glioma patients will be recruited. Patients who are recruited will get treatment of ultra-low dose Bevacizumab plus Temozolomide in ether Hebei Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Glioma
• Recurrent High-grade Glioma

• NCT number: NCT02416999
• Study type: Interventional
• Source: Hebei Yanda Hospital
• Contact: Nan Ji, MD
• Phone: +86 13910713896
• Email: neurochina@gmail.com
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 2015
• Completion date: May 2018